"Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management"

“优化定价、采购和共同开发及其在公共和私营部门药品管理中的应用”

• 批准号: 228649-2012
• 负责人: Zaric, Gregory
• 金额: $ 2.04万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=546901
• 关键词: Optimal; Pricing; Purchasing; Co; Development

I will investigate a number of issues related to optimal purchasing contracts, optimal pricing, and optimal co-development opportunities, all of which are motivated by management problems in the pharmaceutical and biotechnology industries. These topics (pricing, purchasing and co-development) are closely related and tied together by the following trends: 1. The use of cost-effectiveness or net benefits analysis as a criteria for drugs to be listed on formularies; 2. The increasing use of "risk sharing" contracts between drug purchasers, such as government insurance plans, and drug manufacturers; 3. The development of very expensive drugs which are only effective for a portion of the population; and 4. The promise of genetic tests to help identify, and thus target, those who are most likely to benefit from new targeted therapies. These trends lead to a number of challenging management problems for managers of public sector drug plans, as well as manufacturers of drugs and genetic tests. In this research I will develop operations research models to help gain insight into these problems. Note that the focus of this research is not on the clinical or basic science issues underlying these trends but rather on the development of mathematical models to address the management issues, in both the public and private sector, that arise from these trends.

我将研究一些与最优采购合同、最优定价和最优共同发展机会相关的问题，所有这些问题都是由制药和生物技术行业的管理问题引起的。这些主题（定价、采购和共同开发）密切相关，并由以下趋势联系在一起：使用成本效益或净效益分析作为列入处方表的药物的标准；2. 在药品购买者（如政府保险计划）和药品制造商之间越来越多地使用“风险分担”合同；3. 开发只对一部分人有效的昂贵药物；和4。基因测试有望帮助识别并瞄准那些最有可能从新的靶向治疗中受益的人。这些趋势给公共部门药物计划的管理人员以及药物和基因测试的制造商带来了一些具有挑战性的管理问题。在本研究中，我将开发运筹学模型来帮助深入了解这些问题。请注意，本研究的重点不是这些趋势背后的临床或基础科学问题，而是发展数学模型，以解决公共和私营部门因这些趋势而产生的管理问题。